Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 2/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | LAP3 | P28838 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538835 | 0.93 | IL1RN (0.60) | IL1RNERAP2ERAP1PTPN1LTA4H | |
| SCHEMBL30538862 | 0.92 | LTA4H (0.61) | IL1RNERAP2ERAP1LTA4HMME | |
| Hydrochloric Acid SCHEMBL31321913 | 0.89 | ERAP2 (0.56) | IL1RNERAP2ERAP1PTPN1LTA4H | |
| SCHEMBL25901501 | 0.87 | CTSK (0.56) | IL1RNERAP2ERAP1PTPN1LTA4H | |
| SCHEMBL21430307 | 0.86 | REN (0.65) | PTPN1CTSKCTSSCTSL | |
| Hydrochloric Acid SCHEMBL11759463 | 0.86 | CTSK (0.58) | CTSKCTSSCTSL | |
| Hydrochloric Acid SCHEMBL11759454 | 0.86 | CTSK (0.58) | CTSKCTSSCTSL | |
| SCHEMBL30576715 | 0.85 | PTPN1 (0.61) | IL1RNERAP2ERAP1PTPN1LTA4H | |
| SCHEMBL11662651 | 0.84 | PTPN1 (0.64) | IL1RNERAP2ERAP1PTPN1CTSK | |
| SCHEMBL21430300 | 0.84 | REN (0.67) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | IL1RN 995/4885ERAP2 2626/4885ERAP1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.